Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 119

recruiting
3 987
countries
28
conditions
2 109

1 824 trials match your criteria

HER2 positive breast cancer

Not recruiting

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib

Ovarian cancer

Not recruiting

Study of Olaparib for Patients with Advanced BRCA-Mutated Ovarian Cancer After Initial Platinum-Based Chemotherapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Finerenone

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Upadacitinib

Dermatitis atopic

Not recruiting

Study on the Safety and Effects of IMG-007 for Adults with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:IMG-007

Chronic cutaneous lupus erythematosus+2

Not recruiting

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab

Renal cell carcinoma

Not recruiting

Study of V940 and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157

Hypertrophic cardiomyopathy

Not recruiting

Study on the Effects of MYK-224 for Patients with Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986435

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Obinutuzumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab

Plasma cell myeloma+1

Not recruiting

Study Comparing Ciltacabtagene Autoleucel with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed and Lenalidomide-Refractory Multiple Myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.